On July 16, Albemarle fell 5.03% in regular trading, trading at $122.23/share, with turnover of $71.15 million. The decline comes amid a wave of target price downgrades from major investment banks over recent weeks.

Specifically, UBS slashed its target from $264 to $205, Baird from $224 to $178, Rothschild from $188 to $170, and Jefferies from $244 to $211. The consensus mean target price has declined from approximately $225 to around $211, reflecting deteriorating institutional expectations for lithium pricing power and earnings sustainability. The current stock price now trades significantly below most analyst targets, with selling pressure attributed to persistent market concerns over the lithium industry's forward pricing ability.

Notably, the company reported a strong Q1 with net sales up 33% year-over-year to $1.43 billion and adjusted EPS of $2.95 versus the $1.06 estimate. However, the recent downgrades suggest analysts are increasingly cautious about the durability of lithium price recovery beyond the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)